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Abstract: Mutations in RAB (member of the Ras superfamily) genes are increasingly recognized as
cause of a variety of disorders including neurological conditions. While musician’s dystonia (MD)
and writer’s dystonia (WD) are task-specific movement disorders, other dystonias persistently affect
postures as in cervical dystonia. Little is known about the underlying etiology. Next-generation
sequencing revealed a rare missense variant (c.586A>G; p.Ile196Val) in RAB12 in two of three
MD/WD families. Next, we tested 916 additional dystonia patients; 512 Parkinson’s disease
patients; and 461 healthy controls for RAB12 variants and identified 10 additional carriers of rare
missense changes among dystonia patients (1.1%) but only one carrier in non-dystonic individuals
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(0.1%; p = 0.005). The detected variants among index patients comprised p.Ile196Val (n = 6);
p.Ala174Thr (n = 3); p.Gly13Asp; p.Ala148Thr; and p.Arg181Gln in patients with MD; cervical
dystonia; or WD. Two relatives of MD patients with WD also carried p.Ile196Val. The two variants
identified in MD patients (p.Ile196Val; p.Gly13Asp) were characterized on endogenous levels in
patient-derived fibroblasts and in two RAB12-overexpressing cell models. The ability to hydrolyze
guanosine triphosphate (GTP), so called GTPase activity, was increased in mutants compared to
wildtype. Furthermore, subcellular distribution of RAB12 in mutants was altered in fibroblasts.
Soluble Transferrin receptor 1 levels were reduced in the blood of all three tested p.Ile196Val
carriers. In conclusion, we demonstrate an enrichment of missense changes among dystonia patients.
Functional characterization revealed altered enzyme activity and lysosomal distribution in mutants
suggesting a contribution of RAB12 variants to MD and other dystonias.
Keywords: musician’s dystonia; RAB12; GTPase; Transferrin receptor; lysosomal degradation
1. Introduction
Musician’s dystonia (MD) is a task-specific movement disorder that is characterized by painless
muscle incoordination or loss of voluntary motor control while the musician is playing the instrument [1,2].
It occurs in professional instrumentalists with a prevalence of 1–2% [3]. About 20% of MD patients
report a positive family history, including MD or writer’s dystonia (WD) [4]. WD is another form of a
task-specific dystonia involving the fingers, hand, and/or forearm. Symptoms usually appear when a
person is trying to do a task that requires fine motor movements, such as writing. Of note, MD may be
accompanied by additional WD [5]. Thus, MD and WD may share a molecular cause.
However, little is known about the etiology of MD and WD and both environmental and genetic
factors have been discussed. Among the environmental risk factors for MD, extensively trained
maximal fine-motor skills and high levels of anxiety and perfectionism have received increasing
attention over the past few years [6–8]. On the other hand, a considerable genetic contribution is
suggested by its high heritability [4,5]. In a recent genome-wide association study, an intronic variant
(rs11655081) in the arylsulfatase G (ARSG) gene was identified as a potential genetic risk factor [9].
However, known monogenic causes of segmental and generalized dystonia including mutations in
TOR1A, THAP1, and GNAL have been excluded as a major cause in MD [4,10,11].
RAB12, member RAS oncogene family, is part of a large family of small guanosine triphosphate
(GTP)-hydrolyzing enzymes (GTPases) that play an important role in vesicle transport and trafficking
within cells [12,13]. RAB12 regulates the degradation of transmembrane proteins on the membranes of
different cellular compartments including the Golgi complex, endosomes and lysosomes. One well
characterized target of RAB12 degradation includes the transferrin receptor 1 (TFRC) [14–16]. RAB12
is highly expressed in the human brain (The Human Protein Atlas, http://www.proteinatlas.org/
ENSG00000206418-RAB12/tissue) and many RAB genes have been linked to neurological disorders.
For instance, mutations in RAB3 are associated with Warburg Micro syndrome [17], and functional
impairments in RAB7 have been linked to Charcot-Marie-Tooth disease Type 2B [18]. More recently,
mutations in RAB39B were postulated as a rare cause of Parkinson’s disease [19,20].
In the present study, we initially used next-generation sequencing (NGS) in three German families
with autosomal dominantly inherited MD/WD to unravel the presumably monogenic disease cause.
We identified a likely pathogenic variant in the RAB12 gene in two out of three families. Genetic
screening of unrelated patients revealed two additional RAB12 mutation carriers among MD patients.
To confirm a functional effect of the identified mutations, we analyzed the consequences of these RAB12
mutations on GTPase activity, its intracellular localization, lysosomal distribution, TFRC degradation,
and autophagy. Additional RAB12 variants were found in other dystonia patients but were largely
absent in the investigated controls as well as in publically available databases.
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2. Materials and Methods
2.1. Subjects
The study was approved by the ethics committee at the University of Lübeck (Lübeck, Germany,
No 04-180 from 1 July 2005). All participants gave written informed consent. We included a total
of 1906 subjects (Table 1) comprising 241 professional musicians diagnosed with MD, 14 relatives
from four MD families (Figure 1), 74 WD patients, 604 other dystonia patients (Table S1), 512 patients
with Parkinson’s disease (PD), and 461 healthy controls from the population-based control cohort
EPIPARK from Lübeck (Germany) [21]. All subjects were of European origin (mainly German) with
the exception of 86 dystonia patients from South Korea. Three of the MD patients and their families
(Families A–C, Figure 1) were previously reported [4,22] and originated from Germany. The diagnostic
work-up of MD patients included a complete neurological examination and visual inspection while
patients were playing their instruments. All other patients were diagnosed by movement disorder
specialists in Lübeck, Kiel, Tübingen (Germany), Seoul (South Korea), and Belgrade (Serbia).
Table 1. Overview of the sequenced patient and control cohorts.
Next Generation Sequencing Sanger Sequencing Gene Panel Total
MD patients 4 b 237 0 241
Relatives of MD patients 6 a,b 8 0 14
Unrelated WD patients 0 54 20 b 74
Other dystonia patients 0 378 226 b 604
PD patients 0 0 512 512
Healthy controls 0 461 0 461
Total 10 1138 758 1906
MD: musician´s dystonia; WD: writer´s dystonia, PD: Parkinson´s disease; a includes 5 patients with WD;
b All identified mutations were confirmed by Sanger sequencing and all available family members including
unaffected were tested for the respective mutation by Sanger sequencing.
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Figure 1. Pedig es of four musician´s dystonia D) families. Black ymbols represent individuals
with MD, gray symbols mark individuals with D, the dotted filled symbol indicates an individual
with possibly mild, generalized dystonia, and the question mark points to an individual that was
initially reported to have dysto ia which however was not confirmed upon re-evaluation by two
neurologists. L-2329 did not agree to be neurologically examined. A photograph of L-10289 illustrating
her dystonic postures is shown in Figure S1. Patients of Family A were exome sequenced at Atlas
Biolabs (superscript “E”) and three patients of Families B and C underwent genome sequencing at
Complete Genomics (superscript “G”). Additional exome sequencing was performed for individuals of
Families A, B, and D at Centogene (superscript“+E”). Mutational status for the p.Ile196Val mutation in
RAB12 is indicated: +/+ for homozygous carriers; +/− for heterozygous carriers;−/− for non-carriers.
For individuals for whom DNA was available a sample ID number (L code) is shown. Dashed symbols
represent deceased family members.
2.2. Mutation Screening
We initially performed exome or genome sequencing in 2011/2012 in six patients from three
families (Figure 1). Specifically, genome sequencing was carried out in three patients of Families B and
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C (Complete Genomics, Mountain View, AB, Canada) while three patients of Family A were exome
sequenced on an Illumina Genome Analyzer (Atlas Biolabs, Berlin, Germany). Variant calling and
annotation were performed by Complete Genomics and Atlas Biolabs, respectively. Detected variants
were filtered (a) to be exonic or splicing; (b) to affect amino acid sequence (synonymous variants were
discarded); (c) to be rare, with a known frequency < 1% in the database for single nucleotide polymorphisms
(dbSNP132, http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?build_id=132); and (d) to
be shared among definitely affected members within a family (Table S2). We further hypothesized that
at least two of the families shared a mutation in the same gene. Candidate variants were validated by
Sanger sequencing. All available family members were tested for segregation using Sanger sequencing.
We recently (in 2016) repeated exome sequencing in Family A (3 affected) and B (3 affected),
and also included Family D (patient-parent trio) at Centogene, Rostock, Germany using an Illumina
HiSeq 2000 machine and an in-house-annotation pipeline. In each of these families, we filtered for rare,
protein-changing variants that were shared by all affected within a given family (Table S3).
Based on the NGS analyses, a rare variant in RAB12 was the only plausible candidate. Next, we
used Sanger sequencing to screen Exons 2 to 6 of RAB12 in 238 unrelated German MD patients, 54 WD
patients, 378 patients with different forms of dystonia, and 461 unrelated healthy subjects. Exon 1,
which has a high GC content of 78% and thus was difficult to amplify, was tested in all MD and WD
patients as well as in 170 healthy controls. Primer sequences are shown in Table S4.
Furthermore, all exons and exon/intron boundaries of RAB12 were included in an NGS-based
gene panel analysis (Centogene, Rostock, Germany) that was performed for another 246 dystonia and
512 PD patients.
2.3. cDNA Analysis
A synonymous variant (c.276A>G, p.Arg92=) in Exon 2 of RAB12 that was predicted by
MutationTaster to affect splicing of RAB12 was investigated on the RNA level. For this, RNA
was extracted from a blood sample of a carrier using the QIAmp RNA Extraction Kit (QIAGEN,
Germantown, MD, USA). Oligo-dT-Nucleotides of the Maxima First Strand cDNA Synthesis Kit
(ThermoFisher, Waltham, MA, USA) served as primers to synthesize the complementary DNA (cDNA)
by use of reverse transcriptase. PCR was performed with primers in Exons 1 and 4 (Table S4) and the
respective product was inspected for its size and Sanger sequenced.
2.4. Plasmid and Viral Construction
The complete coding sequence of RAB12 (RefSeq: NM_001025300.2) was subcloned into a pcDNA
vector containing a FLAG TM-tag upstream of RAB12. The FLAG-tagged RAB12 sequence was then
introduced into a lentiviral expression vector containing a puromycin resistance cassette. The mutations
(c.38G>A, p.Gly13Asp and c.586A>G, p.Ile196Val) were introduced by site-directed mutagenesis
(QuikChangeII, Stratagene, Cedar Creek, TX, USA, for primers see Table S4). Sequences of all RAB12
constructs were verified by Sanger sequencing. For lentiviral production, Human Embryonic Kidney
(HEK293T) cells were transfected with vectors containing vsv-g envelopes, pCMV delta R8.2, and
expression vectors with the RAB12 constructs using FuGENE HD transfection reagent (Promega,
Madison, WI, USA). The virus was harvested from the supernatant by ultracentrifugation and the
titer was determined using the RETRO-TEK HIV p24 Antigen ELISA (enzyme-linked immunosorbent
assay) (Zeptometrix, Buffalo, NY, USA).
2.5. Cell Culture and Stable Transfection
Skin biopsies were collected from two MD patients carrying the Ile196Val mutation and two
healthy controls. Fibroblasts and SH-SY5Y cells were cultivated in Dulbecco’s modified eagle medium
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (all medium components
were provided by PAA Laboratories, Pasching, Upper Austria, Austria). The cells were incubated at
37 ◦C and 5% CO2 in a humidified atmosphere. Fibroblasts of the MD patients were used to study
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effects of mutations in endogenously expressed RAB12. For overexpression studies, SH-SY5Y cells
and fibroblasts from a healthy control subject were stably transfected with lentivirus (multiplicity of
infection = 5) containing expression vectors with RAB12 wildtype (WT) and mutated cDNA sequences
(c.38G>A, p.Gly13Asp and c.586A>G, p.Ile196Val). Selection of transfected cells was performed with
2 µg/mL puromycin (Sigma, St. Louis, MO, USA).
2.6. GTPase Assay
Proteins from SH-SY5Y cells stably expressing RAB12 WT and mutated proteins were extracted
with an isotonic lysis buffer (15 mM Tris/HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA
(Ethylendiamin-tetraacetat) protease inhibitor cocktail (Roche, Basel, Switzerland)) and subsequently
centrifuged at 4 ◦C at 16,000× g for 20 min. Protein concentration was measured using the Dc
Protein Assay (BioRad, Hercules, CA, USA). Whole protein extracts were used for the measurement of
GTPase activity because effector proteins of RAB12, except for the Guanine nucleotide exchange factor
DENND3 (DENN domain containing 3) [23], are largely unknown. The rate of inorganic phosphate
that was newly produced within one hour of incubation was determined with the ATPase/GTPase
Activity Assay Kit (Sigma), which was used according to the manufacturer’s protocol. Absorption
was measured at 620 nm. The specific GTPase activity was calculated and data were normalized
for the GTPase activity in RAB12 WT in each experiment. Means of four independent experiments
were calculated.
2.7. RAB12 Protein Structure Modeling and Molecular Dynamics Simulations
The X-ray structure of inactive, guanosine diphosphate (GDP)-bound WT RAB12 (Protein
Data Bank [PDB] ID: 2IL1, www.rcsb.org) was prepared using the Protein Preparation workflow
(Schrödinger Suite 2014-2 Protein Preparation Wizard; Epik version 2.8; Impact version 6.3; Prime
version 3.6, Schrödinger, LLC, New York, NY, 2014) [24]. Inactive p.Ile196Val-RAB12 was modeled
with Schrödinger Prime (version 3.6, Schrödinger, LLC, New York, NY, 2014) based on the 2IL1-X-ray.
Active, GTP-bound RAB12 models were built using the RAB1A X-ray structure (Protein Data Bank
(PDB) ID: 3TKL [25], chain A, resolution: 2.18 Å) and the homology-modeling module of Schrödinger
Prime (version 3.6) with default settings. Non-template loops were refined by loop refinement (Prime,
version 3.6). Additionally, the models were optimized employing the OPLS2005 [26] force field
for energy minimization. Validation of the homology models was done using Prosa2003 [27] and
PROCHECK. [28] All molecular dynamics simulations were performed using the Desmond package
(Desmond Molecular Dynamics System, version 3.8, D. E. Shaw Research, New York, NY, USA,
2014) [29] and the OPLS 2005 force field [26]. Prepared X-ray structures and homology models of
RAB12 were used as starting structures; each system was solvated in an orthorhombic box of TIP3P
(transferable intermolecular potential with 3 points)-modeled water molecules [30]. The simulations
were carried out with the default protocol provided in Desmond. Molecular dynamics simulations
were performed at 300 K and 1bar for either 10 ns or 20 ns, if not stable after 10 ns simulation.
2.8. Immunostaining
For immunostaining, patient-derived fibroblasts, control fibroblasts, and fibroblasts stably
expressing WT and mutant forms of RAB12 were cultured on glass cover slips in a 24-well plate. Cells
were fixed with 4% paraformaldehyde (Sigma) and FLAG-tagged RAB12 proteins were detected with a
primary antibody raised against FLAG (1:1000, rabbit, Cell Signaling, Cambridge, UK). For detection of
lysosomes and TFRC, monoclonal antibodies raised against LAMP-1 (lysosomal associated membrane
protein 1) as a lysosomal marker (1:200, mouse, Santa Cruz, Dallas, TX, USA) and TFRC (1:300, mouse,
Invitrogen, Carlsbad, CA, USA) were used. The Endoplasmic reticulum (ER) and the Golgi apparatus
were detected with monoclonal antibodies raised against PDI (1:500, mouse, Abcam, Cambridge,
UK) and 58K Golgi protein (1:50,000, mouse, Abcam), respectively. Alexa fluor 488 and Alexa fluor
568 coupled secondary antibodies (1:400, goat, Life Technologies, Carlsbad, CA, USA) were utilized
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for visualization. Cell nuclei were stained with 1 µg/mL DAPI in DAPI Fluoromount G mounting
medium (Southern Biotech, Birmingham, AL, USA). Images were analyzed with a Zeiss Axiovert
200 M microscope (Zeiss, Oberkochen, Germany) with ApoTome and Axiovision Rel 4.8 software
(Zeiss, Oberkochen, Germany). For each of the three constructs (1 WT, 2 mutants), we randomly chose
areas for analysis. Within these areas, all cells with intact nuclei (in total 110 cells per construct) were
analyzed and assigned to one of three groups according to their properties: (a) RAB12 and lysosomes
were uniformly distributed in the cytosol; (b) RAB12 and lysosomes were located in the perinuclear
region and in large parts of the cytosol; (c) RAB12 and lysosomes accumulated exclusively in the
perinuclear region.
2.9. Autophagy Inhibition and TFRC Degradation
SH-SY5Y cells stably expressing mutant and WT RAB12 were treated with the lysosomal inhibitor
Bafilomycin A1 (3 nM, Sigma) for 24 h. Cells were detached using Accutase (PAA laboratories,
Pasching, Austria) and proteins were extracted with RIPA buffer (50 mM Tris-HCl, pH 7.6, 150 mM
NaCl, 1% deoxycholate (DOC), 1% NP-40 and 0.1% sodium dodecyl sulfate (SDS)). After centrifugation
at 4 ◦C at 16,000× g for 20 min, the proteins of the supernatant were used for Western blot analysis.
Protein concentrations were determined utilizing Dc Protein Assay (BioRad) and 10 µg of the proteins
were loaded on NuPAGE 4–12% Bis-Tris protein gels (Life technologies). Proteins were then transferred
to a nitrocellulose membrane (Protran, AnalytikJena, Jena, Germany) and primary antibodies raised
against FLAG (1:1 × 107, mouse, Sigma), TFRC (1:20,000, mouse, Invitrogen), p62 (1:1000, rabbit, Cell
Signaling), LC3 (1:4000, rabbit, Novus, Wiesbaden Nordenstadt, Germany), and β-actin (1:1 × 106,
mouse, Cell Signaling) were used. The signal intensities of TFRC, p62, β-actin, and LC3 II (light chain 3,
also known as microtubule associated protein 1 light chain 3 alpha) were analyzed densitometrically
with the Totallab 100 v2006 software. For calculations of TFRC degradation, the protein bands of
bafilomycin-treated cells were set to 100%.
2.10. Endogenous TFRC Levels in Patients’ Blood
To test for the concentration of soluble TFRC levels in the blood of available patients from Family A
(L-2283, L-2381, L-2276), we used routine blood count measurements from local medical laboratories.
2.11. Statistical Analysis
To compare frequencies of diseased and healthy RAB12 variant carriers, Chi-square test
(comparison with frequencies in about 60,000 individuals from the Exome Aggregation Consortium
(ExAC) at http://exac.broadinstitute.org/) and Fisher’s exact test (comparison with our control
individuals) were performed. All statistical tests related to the functional assays were performed
with Graph Pad Prism 6. One-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test was
carried out to analyze the effect of RAB12 mutations on the GTPase activity, TFRC degradation, and
the activation of autophagy. A Chi-square test was used for comparison of the cellular distribution of
RAB12 and LAMP-1 in fibroblasts stably expressing WT or mutant RAB12. Likewise, for comparison
of LAMP-1 distribution in patient and control fibroblasts, a Chi-square test was utilized.
3. Results
3.1. Identification of RAB12 Mutations in Patients with Musician’S Dystonia
Next-generation sequencing analyses in 2011/2012 revealed about 25,000 variants per exome
and approximately 3.5 million variants per genome (Table S2). Filtering for rare, exonic and splicing
as well as protein-changing variants shared among affected individuals within families, revealed
83, 509, and 1023 changes in Families A, B, and C, respectively. While there was no gene with rare,
protein-changing variants in affected individuals of all three families, the same rare missense change in
RAB12 (c.586A>G, p.Ile196Val, rs143888944) was found among the four affected patients of Families A
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and C (Figures 1 and 2a). This variant was also detected in the presumably unaffected mother (L-2329)
of the index patient in Family C. She is a 76-year old, retired secretary who did not play a musical
instrument. She did not report any dystonic symptoms on the telephone-based Beth Israel Medical
Center Dystonia Screen (BIDS) but could not be neurologically examined [4].
This RAB12 variant was not detected in 461 ethnically matched controls and has been reported in
GnomAD in the heterozygous state only with a frequency of 0.0003. The p.Ile196Val substitution is
highly conserved (Figure 2b) and predicted to be damaging by MutPred (http://mutpred.mutdb.org/)
and MutationTaster (www.mutationtaster.org), and received a Combined Annotation Dependent
Depletion (CADD) score of 16.5 (http://cadd.gs.washington.edu/) (Table 2).
Next, we searched for genetic variations of RAB12 in other MD patients. Sequencing of all six
coding exons in 238 unrelated MD patients of European ancestry revealed two additional carriers
of rare missense variants (p.Ile196Val, p.Gly13Asp) as well as one carrier of a synonymous change
(p.Arg92=, Tables 2 and 3). The p.Ile196Val substitution was detected in another 39-year old German
MD patient (Patient D, Figure 1). The patient first noticed embouchure problems when playing the
trumpet at the age of 17 years. He changed his instrument and started to study the tuba. At the age
of 21 years, he also developed embouchure dystonia on the tuba and had to stop his musical career.
His father had WD (age at onset: 27 years) and the maternal grandmother as well as the paternal
grandfather were both reported to also suffer from writing problems (Figure 1). Segregation analysis
revealed that the mildly affected mother of Patient D carried the p.Ile196Val variant in the homozygous
state. Upon neurological examination and based on an unblinded as well as a blinded video review
by three independent movement disorder specialists, she displayed several mild motor signs. These
included dystonic posturing of her right hand with flexion of the third to fifth finger and of the thumb
and extension of the index finger, perioral dyskinesia entrained with hand and finger movements,
slowness of finger and hand movements bilaterally, more pronounced on the right-hand side and
accompanied by curling of the third to fifth finger, as well as a 15-degree tilt to the right of her trunk in
keeping with mild axial dystonia (Figure S1). The father was carrier of two WT alleles. He also tested
negative for the GAG deletion in TOR1A (NM_000113.2: c.904_906delGAG, p.Glu303del) and negative
for mutations in other dystonia-related genes [31] by exome sequencing.
The second missense variant (c.38G>A, p.Gly13Asp) was found in a 36-year old percussionist
suffering from MD (Patient E, Figure 2a,b). He developed task-specific dystonia of his right leg when
playing the percussion at the age of 25 years.
The synonymous variant was located near the acceptor splice site of Exon 2 (c.276A>G, p.Arg92=)
and detected in a 39-year old MD patient. The variant was predicted to affect splicing by MutationTaster.
However, analysis of mRNA expression revealed only one transcript and sequencing of the cDNA confirmed
the presence of both alleles, indicating that the variant does not impair splicing (data not shown).
Recent exome sequencing of Families A, B, and D with good coverage (mean coverage depth:
120×, with approximately 95% of bases covered at >20×) excluded known dystonia genes and
confirmed RAB12 as the only plausible candidate (Table S5). Except for variants in MUC4 in Families B
and D, none of the candidate genes from an individual family were found in a second family. MUC4
encodes a mucin that is expressed in epithelial cells and does not represent a convincing candidate
for a neurological disorder. In Family A, B, and D, we identified 60, 46, and 80 individual, rare,
protein-changing variants shared among the affected family members (Table S5).
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Table 2. Detected variants in RAB12 in musician´s dystonia and other dystonia patients as well as in the control group.
Variant
(NM_001025300.2,
NP_001020471.2)
ID Polyphen-2(Score)
Mutation Taster
(Score) MutPred (Score) CADD Score
Allele
Frequency in
MD Patients
Allele Frequency in
Other Dystonia
Patients
Allel
Frequency in
Controls (a)
Allele Frequency in
GnomAD
All/non-Finnish EUR
c.38G>A p.Gly13Asp L-3921 Benign (0.086) Disease causing(0.994) Benign (0.266) 22.4 1/482 0/492 0/1946 0.0006/n.a.
c.276A>G p.Arg92=
rs372618073 L-3799 L-5334 n.a.
Disease causing
(0.999) n.a. 8.2 1/482 0/1356 1/1946 0.0003/0.0006
c.391GA>CT
p.Asp131Leu (b) L-5385 Benign (0.048)
Disease causing
(0.999)
Disease causing
(0.492) 25 0/482 0/1356 1/1946 0.00003/0.00006
c.442G>A
p.Ala148Thr L-1729
Probably
damaging (0.995)
Disease causing
(0.999)
Disease causing
(0.654) 31 0/482 1/1356 0/1946 n.a.
c.520G>A
p.Ala174Thr
rs149427020
L-11086
L-11092
L-11132
Probably
damaging (0.977)
Disease causing
(0.999)
Disease causing
(0.828) 32 0/482
(c) 0/1184 EUR
3/172 EA 0/1 946
(c) 0.0004/0.0064 (d)
c.542G>A
p.Arg181Gln
rs371288995
L-8527 Probablydamaging (0.970)
Disease causing
(0.999) Benign (0.377) 25.3 0/482 1/1356 0/1946 0.00007/0.0001
c.586A>G
p.Ile196Val
rs143888944
L-2381 L-2332
L-3758 L-3781
L-8307 L-9497
Benign (0.323) Disease causing(0.999)
Disease causing
(0.555) 16.5 3/482
(e) 3/1356 0/1946 0.0003/0.0006
c.693G>A p.Pro231= L-5328 n.a. Disease causing(0.999) n.a. 10.5 0/482 0/1356 1/1946 0.00001/0.00002
(a) The control population includes 461 healthy individuals and 512 Parkinson’s disease patients; (b) c.391G>C (p.Asp131His) and c.392A>T (p.Asp131Val) are reported in GnomAD
with the exact same minor allele frequency; (c) Not ethnically matched (patients were of East Asian origin); (d) Since the variant was exclusively found among East Asian patients, the
provided GnomAD frequency is for East Asians instead of Non-Finish Europeans; (e) In addition, two affected relatives with writer’s dystonia also carried this variant. GnomAD: Genome
Aggregation Database at http://gnomad.broadinstitute.org/gene/ENSG00000206418. EUR: Europeans; EA: East Asians; n. a.: not available.
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Table 3. Clinical findings in RAB12 mutation carriers.
ID Variant Sex Age at Onset(Years)
Initial
Symptom
Age
(Years)
Current
Symptoms Family History Ethnicity
L-3921 c.38G>Ap.Gly13Asp male 25 MD 38 MD negative German
L-1729 c.442G>Ap.Ala148Thr female 76
dervical
dystonia 78
torticollis,
essential tremor negative German
L-11086 c.520G>Ap.Ala174Thr male 23 MD 33
task-specific arm
dystonia
(MD + WD)
negative South Korean
L-11092 c.520G>Ap.Ala174Thr male 17 WD 41 torticollis, WD negative South Korean
L-11132 c.520G>Ap.Ala174Thr female 58
dystonia
of the
upper lip
70
torticollis,
oromandibular
dystonia
negative South Korean
L-8527 c.542G>Ap.Arg181Gln female 58
cervical
dystonia 59 torticollis unknown German
L-2381 c.586A>Gp.Ile196Val male 27 MD 44 MD positive German
L-2332 c.586A>Gp.Ile196Val male 31 MD 48 MD negative Dutch
L-3781 c.586A>Gp.Ile196Val male 17 MD 39 MD
positive for
dystonia German
L-3758 c.586A>Gp.Ile196Val female 56
cervical
dystonia 67
torticollis,
shoulder
elevation,
head tremor
positive for
Parkinson´s
disease
German
L-8307 c.586A>Gp.Ile196Val female 70
cervical
dystonia 73
torticollis,
head tremor
positive for
Parkinson´s
disease/tremor
German
L-9497 c.586A>Gp.Ile196Val female 41 WD 53
task-specific arm
dystonia
positive for
Parkinson´s
disease/tremor
German
3.2. RAB12 Variants Are More Frequent in Dystonia Patients
The detection of four MD patients carrying rare missense variants in RAB12 was followed
by genetic analysis of additional patients and controls. Among 74 unrelated WD patients, we
found another carrier of p.Ile196Val (L-9497) and two patients with another substitution (c.520G>A,
p.Ala174Thr, L-11086, L-11092). Of note, the first symptoms in L-11086 occurred in his left hand after
prolonged clarinet playing over two months for more than 10 hours in an army band, indicating that
he actually suffers from MD. Screening of 604 non-MD/WD dystonia patients revealed a total of five
heterozygous carriers of rare missense variants in RAB12 including p.Ile196Val (n = 2), p.Ala174Thr,
c.442G>A (p.Ala148Thr), and c.542G>A (p.Arg181Gln, rs371288995) (Tables 2 and 3).
Among 461 healthy controls, we found one carrier of a rare missense variant (p.Asp131Leu) and
two carriers of synonymous base pair substitutions (p.Arg92=, p.Pro231=) (Table 2). While p.Arg92=
did not affect splicing (see above), an RNA sample of the carrier of the p.Pro231= variant was not
available. Both synonymous variants received a relatively low CADD score (<11) and activation of a
cryptic splice site was not predicted using a splice site prediction tool (http://www.fruitfly.org/seq_
tools/splice.html, donor and acceptor score cutoff: 0.1). In 512 PD patients that were screened using
a GenePanel and served as controls to test for disease specificity of the RAB12 variants, we did not
detect any rare sequence change (Table 2).
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3.3. GTPase Activity Seems to Be Elevated in RAB12 Mutants
We aimed to test whether the RAB12 missense variants identified in MD patients (p.Gly13Asp,
p.Ile196Val) have an impact on the enzymatic activity of the small GTPase RAB12. To compare
the GTPase activity between SH-SY5Y cells stably expressing FLAG-tagged WT, p.Gly13Asp, and
p.Ile196Val forms of RAB12, proteins were isolated in a native buffer and GTP hydrolysis was
performed for one hour. Colorimetric measurements in four independent experiments revealed
that GTP hydrolysis in FLAG-RAB12 p.Gly13Asp expressing SH-SY5Y cells was significantly increased
compared to SH-SY5Y cells expressing FLAG-RAB12 WT (2.3-fold, p = 0.0065, Figure 2c). The GTP
hydrolysis in FLAG-RAB12 p.Ile196Val expressing SH-SY5Y cells seemed also to be increased (1.4-fold)
but the effect did not reach significance. Both mutations are located outside of the predicted GDP/GTP
binding sites (49–57, 97–101, 155–159, and 187–188, www.uniprot.org, Figure 2a) and the predicted
effector protein binding site (amino acids 71–79, www.uniprot.org).
3.4. The p.Ile196Val Mutation Does Not Change the Secondary and Tertiary Structure of RAB12 In Silico
To investigate the impact of RAB12 mutations on the protein structure, in silico modeling was
performed. RAB proteins switch between a GDP- (inactive) and a GTP-bound (active) conformation
and these two protein states differ in the conformation of the switch regions [32]. A RAB12 X-ray
structure (PDB ID: 2IL1, resolution: 2.1 Å) in complex with GDP representing the inactive form is
publically available. Amino acid residue Gly13 is missing in this crystal structure and could not be
modeled. Since no 3D structure of RAB12 in its active conformation is available, homology models
of active, GTP-bound WT- and p.Ile196Val-RAB12 were built. The human RAB1A X-ray structure
(PDB ID: 3TKL [25], chain A, resolution: 2.18 Å), representing the active form, was used as template
(50% sequence identity with RAB12 and covering Arg37-Met208). Homology models of active RAB12
WT and p.Ile196Val were generated (Figure 2d). Gly13Asp was not covered by the template and thus
could not be modeled. Residue 196 is located in an α-helix about 10 Å away from GDP/GTP and its
binding site. Using these models, there was no major effect on GDP/GTP binding or protein structure
comparing the molecular dynamics simulations of WT- and p.Ile196Val-RAB12 (inactive and active,
data not shown).
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Figure 2. RAB12 and  functionally  investigated variants.  (a) Schematic view of  the RAB12 protein 
with  the  identified  mutations  p.Gly13Asp  and  p.Ile196Val  in  MD  patients  (red  arrows),  the 
guanosine  diphosphate/guanosine  triphosphate  (GDP/GTP)‐binding  sites  (red),  the  predicted 
effector  region  (blue),  and  the  posttranslational  modifications  on  amino  acid  positions  1 
(N‐acetylation),  21,  25,  106  (phosphorylations),  243,  and  244  (geranylgeranylations)  are  indicated. 
RefSeq: NM_001025300.2, NP_001020471;  (b) The Glycine  at position  13  (left panel,  red)  and  the 
Isoleucine at position 196  (right panel,  red) are  conserved across different  species;  (c) Proteins of 
transfected SH‐SY5Y cells were  incubated with GTP  for 1 h and PO43− production was measured. 
GTPase activity of mutant RAB12 expressing cells was normalized for GTPase activity of wild‐type 
(WT)  RAB12  expressing  cells.  The  bars  indicate  the means  ±  standard  error  of mean, One‐way 
analysis of variance (ANOVA) with Bonferroni’s post‐hoc test. ** p < 0.01, n = 4; (d) Homology model 
of  active/GTP‐bound RAB12  in  ribbon  representation. WT  is presented  in  black  (left model)  and 
p.Ile196Val in blue (right model). Magnesium ions are shown as green spheres, amino acid residue 
196 is marked by red points, and GTP is indicated by sticks. The figures were generated with PyMOL 
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accumulation in the patient fibroblasts compared to controls (controls: 17% and 18%, patients: 24%
and 31%, p = 0.0002).
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3.6. Soluble TFRC Levels in Patients’ Blood Were Reduced 
It  has  been  reported  that  RAB12  regulates  the  degradation  of  TFRC  [15]. All  three  tested 
patients with  the  p.Ile196Val mutation  showed  reduced  soluble TFRC  levels  in  blood  (Table  4). 
While in both female WD patients soluble TFRC levels at 0.7 and 0.8 mg/L were only slightly below 
the reference range (0.83–1.76 mg/L), levels in the male MD patient at 1.7 mg/L were more clearly 
below  the  reference  range  (2.2–4.99 mg/L).  Except  for  the  Transferrin  level which was  slightly 
decreased  in  the  male  patient  (2.3  g/L,  ref:  2.50–3.80g/L),  all  other  parameters  reflecting  iron 
metabolism were in the normal range in all three patients (Table 4). 
Table 4. Results of blood count for members of Family A with the p.Ile196Val mutation. 
Parameter (Reference)   
Female Patient with WD 
(L‐2276)   
Female Patient with WD 
(L‐2283)   
Male Patient with MD 
(L‐2381)   
Erythrocytes (Mio/μL)    4.5  4.5  4.5 
(4.20–5.40)  (4.20–5.40)  (4.5–5.9) 
Hemoglobin (g/dL)  13.6  13.8  14 
(12.0–16.0)  (12.0–16.0)  (14.0–17.5) 
Hematocrit (%)  42  40.5  43 
(37.0–47.0)  (37.0–47.0)  (40–53) 
Figure 3. RAB12 mutations changed the subcellular localization of RAB12 proteins and lysosomes.
(a) Ectopical protein expression of FLAG-RAB12 and expression of the lysosome-associated protein
LAMP-1 (lysosomal associated membrane protein 1) is equal in RAB12 WT and mutant SH-SY5Y cells.
All protein signals were detected on the same membrane. Blots were cropped for clarity but no bands
were removed. Original blots are shown in the supplementary material (Figure S5); (b) In WT and
mutated RAB12-overexpressing cells, three different patterns of RAB12 distribution were observed and
categorized. Proportions of cells revealed RAB12 (red) that was evenly distributed in the cytoplasm
(upper left panel), that was distributed in the cytoplasm and accumulated in close proximity to the
nucleus (upper middle panel), or that accumulated exclusively in the perinuclear region of the fibroblast
(upper right panel). FLAG-RAB12 and LAMP-1 (green) colocalized in the cytoplasm (lower panels).
Nuclei were stained with DAPI (blue). Scale bar: 20 µm; (c) 110 randomly chosen fibroblasts with
each construct were categorized and cellular localization of FLAG-RAB12 and LAMP-1 was quantified.
Chi-square test: p < 0.0001; (d) 110 randomly chosen fibroblasts of two MD patients (p.Ile196Val) and
two healthy controls were categorized and cellular localization of LAMP-1 was quantified. Chi-square
test: p = 0.0002.
3.6. Soluble TFRC Levels in Patients’ Blood Were Reduced
It has been reported that RAB12 regulates the degradation of TFRC [15]. All three tested patients
with the p.Ile196Val mutation showed reduced soluble TFRC levels in blood (Table 4). While in both
female WD patients soluble TFRC levels at 0.7 and 0.8 mg/L were only slightly below the reference
range (0.83–1.76 mg/L), levels in the male MD patient at 1.7 mg/L were more clearly below the
reference range (2.2–4.99 mg/L). Except for the Transferrin level which was slightly decreased in the
male patient (2.3 g/L, ref: 2.50–3.80g/L), all other parameters reflecting iron metabolism were in the
normal range in all three patients (Table 4).
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Table 4. Results of blood count for members of Family A with the p.Ile196Val mutation.
Parameter (Reference)
Female Patient with WD
(L-2276)
Female Patient with WD
(L-2283)
Male Patient with MD
(L-2381)
Erythrocytes (Mio/µL) 4.5 4.5 4.5
(4.20–5.40) (4.20–5.40) (4.5–5.9)
Hemoglobin (g/dL) 13.6 13.8 14
(12.0–16.0) (12.0–16.0) (14.0–17.5)
Hematocrit (%)
42 40.5 43
(37.0–47.0) (37.0–47.0) (40–53)
Ferritin (ng/mL) 31.2 28.4 276
(10.0–291.0) (10.0–291.0) (18–360)
Transferrin (g/L) 2.4 2.6 2.3
(2.0–3.8) (2.0–3.8) (2.50–3.80)
Fe2+ (µg/dL)
75.2 102.6 81
(50.0–170.0) (50.0–170.0) (61.5–156.46)
Soluble Transferrin
receptor (mg/L)
0.8 0.7 1.7
(0.83–1.76) (0.83–1.76) (2.20–4.99)
3.7. Colocalization of RAB12 and TFRC and Degradation of TFRC Was Unchanged in RAB12 Mutants
RAB12 colocalizes with the transmembrane receptor TFRC, which is possibly taken up by
endocytosis and recycled back to the cell membrane via recycling endosomes or degraded via the
lysosomal pathway [15]. We confirmed colocalization of FLAG-RAB12 and TFRC in fibroblasts
overexpressing WT RAB12 and demonstrated colocalization also for mutated RAB12 (p.Gly13Asp,
p.Ile196Val, Figure S2). Due to enhanced GTPase activity of RAB12 mutants, lysosomal degradation of
TFRC might be altered. To exhibit physiological receptor function, TFRC forms dimers. Therefore, we
investigated the degradation of dimeric TFRC in WT and mutated FLAG-RAB12-expressing fibroblasts
and SH-SY5Y cells, and in patient fibroblasts. Inhibition of lysosomal acidification by treatment with
Bafilomycin A1 for 24 h led to accumulation of dimeric TFRC in all three cellular models in RAB12 WT
and mutant cell lines (Figure S3) but no difference on TFRC degradation was observed dependent on
the RAB12 form. After 24 h, about 20–40% of TFRC were degraded (Figure S3).
3.8. Autophagy Is Not Impaired in SH-SY5Y Cells Overexpressing RAB12 Mutants
Since we observed an altered distribution of lysosomes in cells expressing mutant RAB12 and
as RAB12 regulates the degradation of the amino acid transporter SLC36A4 (solute carrier family 36
member 4, also known as PAT4) [16], a regulator protein of mTOR (mammalian/mechanistic target of
rapamycin complex 1)-dependent autophagy, we hypothesized that autophagy might be disturbed
in RAB12 mutants. To assess the autophagy flux, we analyzed conversion of the autophagy marker
MAP1LC3A (LC3) by Western Blot. Upon activation of autophagy, LC3 translocates from the cytosol
to the autophagic membrane and converts from its ‘inactive’ form LC3-I into an autophagy-related
form LC3-II [33]. Treatment of SH-SY5Y cells expressing FLAG-RAB12 WT and mutated RAB12 with
3 nM Bafilomycin A1 for 24 h, raised the levels of lipidated active LC3-II protein (Figure S4a), which
is a component of the autophagosome membrane. The LC3-II levels relative to ß-actin levels were
calculated as a measurement of activation of autophagy and were demonstrated to be not significantly
elevated in mutated FLAG-RAB12 expressing SH-SY5Y cells (p.Gly13Asp: +1.2-fold; p.Ile196Val:
+1.1-fold) compared to the FLAG-RAB12 WT expressing cells (Figure S4b, p = 0.2). Protein levels of
p62, a sensor for toxic cellular waste that accumulates when autophagy is impaired, were not altered in
SH-SY5Y cells expressing mutant FLAG-RAB12 compared to WT FLAG-RAB12 proteins (Figure 3c,d).
4. Discussion
We here report an enrichment of rare missense variants in dystonia patients (12/919, 1.3%),
particularly in patients with MD (5/242, 2.1%) compared to healthy controls (1/461, 0.2%) and PD
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patients (0/512). Specifically, we detected the p.Ile196Val substitution in 3 of 241 patients of our
specifically recruited MD patients and in two relatives with WD as well as in one unrelated WD
patient. Rare missense variants in two additional MD patients included p.Gly13Asp and p.Ala174Thr.
The latter change was found in a patient of South Korean origin who was initially grouped among the
WD patients but co-incidentally also suffered from MD. Ala174Thr was also found in a patient with
segmental dystonia including WD. A total of 5 additional carriers of rare variants were found among
604 patients with other forms of dystonia (cervical dystonia) including two carriers of p.Ile196Val,
as well as one carrier each of a p.Ala174Thr, p.Ala148Thr, or p.Arg181Gln substitution. There were no
family members available to test for segregation but all missense changes received a CADD score > 15
and were extremely rare (<0.0006) in public databases, including GnomAD (genome aggregation
database, Table 2).
For statistical analysis, we compared the number of missense variant carriers in dystonia patients
(10/916, not including the initial families) and the non-dystonic subjects (1/973) which yielded a
significant p-value of 0.005 (two-tailed Fisher´s exact test). Although this included three South Korean
dystonia patients for whom we did not have ethnically matched controls, the difference for our overall
study remains significant even when focusing on Caucasians by taking out the 86 South Korean
patients (7/830 vs. 1/973, p = 0.0278 [Fisher´s exact test]). Of note, the Ala174Thr that we found in
three South Korean patients is found almost exclusively in the East Asian population with a carrier
frequency of 120/18864 in GnomAD (http://gnomad.broadinstitute.org/variant/18-8636254-G-A)
and seems to be enriched in dystonia patients (albeit not statistically significant; 3.5% vs. 1.3%).
RAB12 is located on chromosome 18p11.22 and the encoded protein belongs to a large family of
small GTPases, which play an important role in vesicle transport and trafficking within cells [12,13].
RAB12 is reported to be located on the membranes of different cellular compartments, including
the Golgi complex, endosomes, and lysosomes where it regulates degradation of transmembrane
proteins [14–16]. Of note, we here demonstrated colocalization with a lysosomal marker but not with
the ER or the Golgi complex.
Our in vitro studies focused on the two initially identified missense variants (p.Gly13Asp and
p.Ile196Val) in RAB12 among MD patients and revealed functional alterations, indicating several
lines of support for a possible pathogenic role of these substitutions in RAB12. This includes an
increased GTPase activity that was observed for RAB12 mutant cells despite the localization of the
mutations outside of the reported GTP-binding sites of RAB12. This elevated enzymatic activity could
not be explained by 3D modeling and simulations of p.Ile196Val. Of note, the Gly13Asp variant that
showed a >2-fold increase in GTPase activity, could not be modeled due to lack of a suitable template.
Considering the same genetic background in RAB12 overexpressing SH-SY5Y cells, an indirect effect
of RAB12 mutations on GTP hydrolysis is also possible. Interestingly, we observed perinuclear
accumulation of RAB12 and lysosomes in cells with RAB12 mutations, which may be related to the
altered GTPase activity. This idea is supported by recently published findings showing perinuclear
clustering of constitutively active RAB12 in RBL-2H3 (rat basophilic leukemia) cells [34].
Furthermore, RAB12 is thought to be involved in iron metabolism by regulating the degradation of
TFRC [15]. Cells take up transferrin-bound TFRC via receptor-mediated endocytosis. This mechanism
is essential for iron uptake in neural tissue [35]. Of note, iron deficiency is implicated in some
types of neurodegeneration [36]. Furthermore, in several genetic forms of neurodegeneration
with brain iron accumulation (NBIA), dystonia (DYT) is a prominent feature of the disease such
as in NBIA/DYT-PANK2 [37], NBIA/DYT/PARK-PLA2G6 [38], NBIA/DYT/PARK-CP [39], and
NBIA/DYT-DCAF17 [31,40]. Interestingly, in all three tested patients from Family A, the levels of
soluble blood TFRC were reduced.
Besides the reported regulatory impact of RAB12 on TFRC degradation, RAB12 is thought to
play a role in the initiation of autophagy [16]. We speculated that elevation of the GTPase activity and
alteration of the subcellular localization of lysosomes in the mutants may have an impact on autophagy.
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We found a slight increase in relative LC3II protein levels in RAB12 mutants but p62 levels were not
affected, indicating a rather minor effect of the RAB12 mutations on activation of autophagy.
Despite RAB12’s important role and plausible link between its function and a neurological disease,
screening of additional patient cohorts is warranted to confirm the pathogenicity of RAB12 mutations in
dystonia patients. The incomplete segregation in Families C and D as well as the relatively high number
(n = 83) of carriers of the p.Ile196Val mutation among approximately 140,000 seemingly unaffected
individuals in GnomAD are at first glance not compatible with the hypothesis of a pathogenic role of
RAB12 mutations in MD. However, it is conceivable that the affected father of Patient D who carries
two RAB12 WT alleles and has WD without other neurological symptoms, presents a phenocopy with
a different disease cause. Phenocopies are not an infrequent observation, especially in the context of
hereditary movement disorders [41]. Furthermore, there is the possibility that the missing disease
phenotype in both the mother of Patient D—in contrast to the maternal grandmother - and mother of
Family C could be explained by reduced penetrance, a phenomenon often seen in dystonia and other
disorders [42]. For instance, penetrance of the GAG deletion in TOR1A is reduced to only 30% [43]
and 30 presumably unaffected carriers are included in GnomAD (http://gnomad.broadinstitute.org/
variant/9-132576340-TCTC-T). Protective genetic variants as well as environmental triggering or
other tutelary factors are under discussion in the development of MD [8]. The argument of reduced
penetrance can also be applied to the 83 variant carriers in GnomAD. Supporting this idea, having
or developing a focal dystonia in the future would not exclude individuals from being included into
GnomAD. Similarly, in our about 1000 non-dystonia samples, we also detected only one carrier of a
rare missense RAB12 variant. Of note, the age at onset in our patients was up to 76 years, i.e., late-onset.
In theory, developing MD requires extensive training and professional performance in playing an
instrument, e.g., in a pianist training especially the fingers of the right hand for ~26,000 h before the
average onset of MD [44]. Thus, an accumulating pathological effect (e.g., on TFRC degradation or
autophagy) in specific brain regions is conceivable as disease mechanism but cannot be investigated in
a cellular model.
Several of our results support the idea of a possible pathogenic role of RAB12 mutations in MD
and probably also other dystonias including increased GTPase activities, altered lysosomal distribution,
reduced levels of soluble TFRC in patients, and the finding that RAB12 mutations were found with a
higher frequency in dystonia patients than in controls. Of note, RAB12 seems to be a highly invariable
gene. Except for the six listed missense and two synonymous variants (Table 2) we did not detect
any additional variant in RAB12 among the almost 2000 screened individuals. The invariance of the
244-amino acid protein RAB12 is also underlined by the presence of only 55 missense and a single
loss-of-function variant in ExAC (http://exac.broadinstitute.org/gene/ENSG00000206418). The ExAC
z-score of 1.63 for missense variants indicates that the number of observed variants in RAB12 was
lower than the expected number reflecting decreased tolerance to missense variations in the RAB12
coding sequence [45]. The intolerance to loss-of-function changes is relatively high with a pLI score
(probability of loss-of-function intolerance) of 0.72 [45], which also points to an important functional
role of the RAB12 protein in humans. For comparison, in another, similarly sized dystonia-linked
protein (THAP1 [THAP domain containing 1], 213 amino acids), ExAC reports a missense z-score of
1.35 and a pLI score of 0.90 while in CDKN1A, a protein of only 164 amino acids and not (yet) linked
to any disease, more missense and loss-of-function variants were observed than expected resulting in
a lower missense z-score and pLI score, respectively (z = 0.01, pLI = 0.03).
5. Conclusions
Taken together, we provide first insights into a possibly pathological function of mutated RAB12
in MD and other forms of dystonia. Screening of more MD patients for mutations in RAB12 is necessary
to confirm RAB12 as a gene for MD. To shed further light on the pathophysiological mechanism of
RAB12, studies on the endogenous level in neuronal cells are warranted.
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Figure S5: Original Blots of Figure 3a. Table S1: Demographic data of 604 other dystonia patients tested for
mutations in the RAB12 gene; Table S2: Initial NGS variant calls; Table S3: Filter steps of variants generated with
recent exome sequencing (Centogene) in Families A, B, and D; Table S4: Primer sequences for Sanger sequencing
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